A Brain Tumor Is Not a Single Disease
Brain tumors are divided into primary (arising from the brain) and metastatic (spreading from elsewhere in the body). Primary tumors include glioma of varying grades (astrocytoma, oligodendroglioma, glioblastoma), meningioma — 90% of which are benign and arise from the meninges — pituitary adenoma with possible hormonal effects, acoustic neuroma (vestibular schwannoma) arising from the balance nerve, and lymphoma (PCNSL) which behaves systemically. Metastatic tumors most often originate from the lung, breast, melanoma, kidney and colon and are frequently multifocal. The treatment plan is personalised according to the tissue diagnosis (pathology), genetic markers (IDH, MGMT, 1p/19q) and the patient's general condition. A diagnosis of 'brain tumor' alone is therefore not a treatment prescription; the right question is 'which tumor, where, and with what biology'.
'Maximal Safe Resection' and Modern Technologies
Contemporary brain tumor surgery has a single principle: protect healthy functional brain tissue while removing the tumor. The volume of tumor removed, especially in gliomas, directly affects survival and time to recurrence; preserved function determines the patient's quality of life. An overly aggressive resection can cause loss of strength or speech, while an inadequate resection can lead to early recurrence. Technologies that balance this include high-magnification microscope/exoscope, MRI/CT-based neuronavigation, functional MRI and DTI tractography to map motor and language pathways before surgery, awake craniotomy for tumors near functional areas, and fluorescence-guided (5-ALA) resection that makes glioma tissue visible under light. Not all of these are needed in every patient; the location of the lesion and surgical experience determine which are used. In some cases sound anatomical knowledge and a microscope are sufficient.
When Is Surgery First-Line, and When an Alternative?
Surgery is the first choice in: symptomatic or rapidly growing meningioma, glioma in a resectable location, pituitary adenoma causing visual loss or secreting hormones (via the endoscopic transsphenoidal route), a solitary brain metastasis accompanying a controlled primary disease, and childhood embryonal tumors. By contrast, in some tumors surgery alone is insufficient or an alternative is more appropriate: in lymphoma (PCNSL) treatment is not resection but biopsy followed by chemotherapy and radiotherapy; in deep-seated gliomas such as the brainstem or thalamus, biopsy and radiotherapy/Gamma Knife come to the fore; with more than five metastases, Gamma Knife or whole-brain radiotherapy is preferred; for a small asymptomatic meningioma or small acoustic neuroma, surveillance or Gamma Knife is considered. The decision is always multidisciplinary: neurosurgeon, neuroradiologist, radiation oncologist and medical oncologist evaluate together. A team decision improves outcomes more than the opinion of a single specialist.
The Surgical Process and Recovery
Preparation includes a detailed neurological and cognitive examination, contrast MRI, functional MRI and DTI tractography where needed, a multidisciplinary meeting and anaesthetic assessment; in some cases preoperative steroids are given to reduce oedema. The patient is positioned according to tumor location; most cases are performed under general anaesthesia, and tumors near functional areas awake when required. As narrow a shave as possible within the hairline is sufficient; shaving the entire head is now rarely necessary. The bone flap is removed, the dura is opened, the tumor is removed under the microscope with navigation, haemostasis is achieved and the layers are closed individually. The procedure can take 2–8 hours depending on tumor type. Afterwards there is usually 24–48 hours of intensive care, followed by a total hospital stay of 3–7 days; a control MRI assesses the extent of resection, and adjuvant treatment (radiotherapy/chemotherapy) is planned according to the pathology if needed. Recovery is 4–6 weeks in benign uncomplicated cases and may reach 3–6 months in high-grade tumors requiring adjuvant therapy.
Risks and Realistic Expectations
Brain tumor surgery is major surgery and its risks must be discussed honestly: bleeding, infection, temporary or permanent neurological deficit depending on tumor location (risk to strength near the motor cortex, to language near the speech area, to the visual field near the visual pathway), brain oedema lasting a few days after surgery, seizures and rarely a CSF leak. These rates vary with the location and size of the tumor, the patient's age and comorbidities; an experienced team and multidisciplinary planning markedly reduce them. Outcomes differ greatly by tumor type: in benign meningioma long-term control is usually possible; in low-grade glioma long-term control can be achieved but recurrence is possible; in high-grade tumors such as glioblastoma the goal is to prolong time while preserving quality of life. We do not promise a guaranteed outcome; expectations are shared openly with the patient and family before surgery. False optimism harms the result of treatment.